US DEA eyes schedule IV restrictions for Eisai's Lusedra
This article was originally published in Scrip
Executive Summary
The US Drug Enforcement Administration (DEA) has proposed classifying Eisai's sedation drug Lusedra (fospropofol) as a schedule IV controlled substance.